000			02900nam a22002897a 4500
003			OSt
005			20240305193719.0
008			221102b |||||||| |||| 00| 0 eng d
028			_b Phone: +255 28 298 3384
028			_b Fax: +255 28 298 3386
028			_b Email: vc@bugando.ac.tz
028			_b Website: www.bugando.ac.tz
040			_cDLC
041			_aEnglish
100			_aEmmanuel Kimaro _926657
245			_aFormulation development of chewable albendazole tablets with improved dissolution rate
260			_aMwanza: _b Elsevier & _b Tanzania Catholic University of Health and Allied Sciences [CUHAS – Bugando] _c2019/12/1
300			_aPages e02911
490			_v Journal Heliyon Volume 5 Issue 12
520			_aAbstract Background Albendazole is an orally administered broad-spectrum anthelmintic. Currently it is mostly used in the treatment of soil transmitted helminthes, hydatidosis and neurocysticercosis caused Taenia solium. Aim of the study. To develop and optimize a formulation of chewable albendazole tablet with improved dissolution rate. Methodology This study was specifically focused on formulation development which passes compatibility studies and optimization of the developed formulation. The formulations were evaluated on assay, dissolution, friability, hardness, weight variation, disintegration and similarity in comparison with the reference product on the market. Analysis was required to be undertaken by High performance thin layer chromatography (HPTLC) analytical methods. Design of Expert version 7 software was used for selection or making scientific decisions in selecting the best composition of the best formulation. Results Five formulations out of ten (F-6, F-7, F-8, F-9 and F10) had all parameters in acceptable range. On optimization, one formulation with independent variables, Sodium Laury Sulphate (SLS) 1.911%, polyvinyl pyrrolidone (PVP-K30) 3.128%, and Sodium Cross carmellose (CCM) 4.95% was selected out of ten predictions made with Design expert version 7.0. It was found that assay of the best formulation is 99.23% which was within the in-house assay specification 95–105%. Dissolution single point in 30 min was found to be 91.5% disintegration between 2-5 min and friability 0.45%.The optimized formulation was tested and found to be within the acceptable limits. The formulation was comparable to the reference product on the market with similarity factor (f2) 62 and difference factor (f1) of 6 at pH1.2. Conclusion A new generic albendazole tablet with improved dissolution rate was formulated, developed and optimized by using a wet granulation method.
700			_aProsper Tibalinda _944994
700			_aRaphael Shedafa _944995
700			_a Mary Temu _944996
700			_aEliangiringa Kaale _944997
856			_uhttps://doi.org/10.1016/j.heliyon.2019.e02911
942			_2ddc _cVM
999			_c19237 _d19237